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Abstract
The sigma 1 receptor (S1R) is widely expressed in the CNS and is mainly located on the endoplasmic reticulum.
The S1R is involved in the regulation of many neurotransmission systems and, indirectly, in neurodegenerative
diseases. The S1R may therefore represent an interesting neuronal biomarker in neurodegenerative diseases
such as Parkinson’s (PD) or Alzheimer’s diseases (AD). Here we present the characterisation of the
S1R-specific 18F-labelled tracer 18F-IAM6067 in two animal models and in human brain tissue.
Methods: Wistar rats were used for PET-CT imaging (60 min dynamic acquisition) and metabolite analysis (1,
2, 5, 10, 20, 60 min post-injection). To verify in vivo selectivity, haloperidol, BD1047 (S1R ligand), CM398 (S2R
ligand) and SB206553 (5HT2B/C antagonist) were administrated for pre-saturation studies. Excitotoxic lesions
induced by intra-striatal injection of AMPA were also imaged by 18F-IAM6067 PET-CT to test the sensitivity of
the methods in a well-established model of neuronal loss. Tracer brain uptake was also verified by
autoradiography in rats and in a mouse model of PD (intrastriatal 6-hydroxydopamine (6-OHDA) unilateral
lesion). Finally, human cortical binding was investigated by autoradiography in three groups of subjects (control
subjects with Braak ≤2, and AD patients, Braak >2 & ≤4 and Braak >4 stages).
Results: We demonstrate that despite rapid peripheral metabolism of 18F-IAM6067, radiolabelled metabolites
were hardly detected in brain samples. Brain uptake of 18F-IAM6067 showed differences in S1R anatomical
distribution, namely from high to low uptake: pons-raphe, thalamus medio-dorsal, substantia nigra,
hypothalamus, cerebellum, cortical areas and striatum. Pre-saturation studies showed 79-90% blockade of the
binding in all areas of the brain indicated above except with the 5HT2B/C antagonist SB206553 and S2R ligand
CM398 which induced no significant blockade, indicating good specificity of 18F-IAM6067 for S1Rs. No
difference between ipsi- and contralateral sides of the brain in the mouse model of PD was detected. AMPA
lesion induced a significant 69% decrease in 18F-IAM6067 uptake in the globus pallidus matching the neuronal
loss as measured by NeuN, but only a trend to decrease (-16%) in the caudate putamen despite a significant 91%
decrease in neuronal count. Moreover, no difference in the human cortical binding was shown between AD
groups and controls.
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Conclusion: This work shows that 18F-IAM6067 is a specific and selective S1R radiotracer. The absence or
small changes in S1R detected here in animal models and human tissue warrants further investigations and
suggests that S1R might not be the anticipated ideal biomarker for neuronal loss in neurodegenerative diseases
such as AD and PD.
Key words: Sigma 1 receptor; PET radiotracer; Parkinson’s disease; Alzheimer’s disease; animal model

Introduction
Sigma receptors have drawn particular interest
over the years as potential biomarkers of
neurodegeneration [1-4]. Pharmacological studies
have reported the evidence of at least two subtypes,
i.e. sigma 1 (σ1) and sigma 2 (σ2) receptors [5, 6]. The
σ1 receptor (S1R) is a highly conserved 25 kD
molecular chaperone protein with 223 amino acids [6,
7]. In vitro crystallography revealed that the S1R is
found in a homotrimeric form with 1 transmembrane
region per protomer [8], although in vivo studies and
sequence-based models support 2 transmembrane
domains, which according to Penke et al. suggest a
“potentially amorphous intrinsically disordered in
vivo structure” of S1R [6]. The S1R is expressed mostly
in the brain, in neurons, oligodendrocytes and
ependymal cells, but also in peripheral organs and
tissue (for review see [6]). At a cellular level, S1R is
mainly located at the endoplasmic reticulum (ER), in
close
contact
with
mitochondria
at
the
mitochondria-associated ER membrane (MAM) [6, 9],
although S1R can easily translocate to the plasma
membrane, the nuclear envelope or interact with
cytosolic proteins with consequences for regulation of
Ca2+ signalling associated cell survival (for review see
[6] & [9]).
The S1R is involved in the regulation of many
neurotransmission systems such as cholinergic,
noradrenergic and dopaminergic systems [10],
although its exact role is still poorly understood. This
neuro-modulatory role means that S1R is indirectly
involved in various neuropathology, including
schizophrenia, depression, stroke, Parkinson’s disease
(PD) and Alzheimer’s disease (AD) [1, 11, 12]. Some
studies have shown a link between S1R dysregulation
and amyotrophic lateral sclerosis, AD or PD
progression [3, 13-16]. Other studies have
demonstrated that there is a reduction in the anterior
putamen S1R density in PD patients [17] and also a
reduction in cortical and cerebellar S1R density in
brains of AD patients [18] and in AD post-mortem
tissues [19, 20]. S1R expression has therefore been
envisaged as a potential biomarker for neuronal
function in health and diseases.
Previously developed S1R PET radiotracers had
limited and variable affinity and/or selectivity
towards S1R, with most of them displaying some

capacity to bind σ2 receptors and/or other
neuro-receptors (for review see [21, 22]). Amongst the
S1R radiotracers, 11C-SA4503 (Ki = 4.4 nM, Ki σ2/σ1 =
55) [23] has been the most used [18, 24, 25] with other
tracers presenting various levels of selectivity (for
review see [22]). Amongst all the [18F]-labelled S1R
radiotracers, 18F-FTC-146 (Ki = 2.5 pM, Ki σ2/σ1 =
144,800) [26], 18F-fluspidine (Ki = 0.59 nM, Ki σ2/σ1 =
1330) [27] and 18F-IAM6067 (Ki = 2.6 nM, Ki σ2/σ1 =
187), presented here, are the most selective for S1R vs
S2R [22, 28]. Selectivity of 18F-IAM6067 for S1R against
a broad range of receptors and transporters has been
previously reported by Moussa et al. (see
supplementary information in [29] where 18FIAM6067 is compound #30). Although affinity and
selectivity
are
essential
criterion,
in vivo
pharmacokinetics is an equally important parameter
as recent studies have shown that 18F-FTC-146 had
unfavourably slow pharmacokinetic properties for
human use [30, 31]. Noteworthily, it was shown in
non-human primate that despite having lower affinity
(S)-18F-fluspidine (Ki = 2.30 nM) displayed more
favourable pharmacokinetics for human use than
(R)-18F-fluspidine (Ki = 0.52 nM) [32]. Hence, taking
into account all these considerations, to date
(S)-18F-fluspidine appears to be the most suitable
candidate for S1R PET imaging in human.
In this study, we present the validation of the
S1R specific 18F-labelled tracer 18F-IAM6067 [28]
(Figure 1). The specificity towards S1R was initially
evaluated in a Papio hamadryas baboon pre-treated
with haloperidol (1 mg/kg, i.v.) which resulted in a
80% displacement in specific receptor binding in all
areas of the brain [28]. Therefore, the aims of this
study were to fully evaluate the in vivo brain uptake of
18F-IAM6067 using in vivo PET imaging; we also tested
its specificity and selectivity for S1R, S2R and 5HT2B as
Moussa et al. [29] reported some affinity for those
receptors (Ki σ2/σ1 = 187, Ki 5HT2B/σ1 = 37). In vivo data
were confirmed by in vitro autoradiography.
Furthermore to investigate the potential of S1R as
neuronal biomarker, we studied 18F-IAM6067 binding
in vivo and by autoradiography in a model of AMPA
lesion in Wistar rats, by autoradiography in a mouse
model of PD, and in AD human tissue as classified by
Braak staging [33].
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Figure 1. Chemical structure of N-(2-Benzofuranylmethyl)-N’-[4-(2-fluoroethoxy)benzyl]piperazine (18F-IAM6067).

Materials and Methods
Radiosynthesis
N-(2-Benzofuranylmethyl)-N’-[4-(2-fluoroethox)
benzyl]piperazine (IAM6067) was labelled with [18F].
The radiosynthesis was previously described by
Moussa and colleagues [28].

Animals
Forty male Wistar rats (Charles River, Margate,
UK) were used for in this study. Animals weighed 378
± 121 g at the time of experimentation and were kept
under a 12-hour light/dark cycle under steady
temperature and humidity with access to food and
water ad libitum. All procedures were carried out in
accordance with the Animals (Scientific Procedures)
Act 1986, and the specific project licence was
approved by the UK Home Office.

Metabolite analysis in plasma and brain
Twenty-four rats were anesthetized using
isoflurane (induction 4-5%, 2-2.5% thereafter in
70%/30% NO2/O2 mixture at 1 L/min) and
catheterized (Jelco® I.V. catheter 24G) in the tail vein
for 18F-IAM6067 administration (32-123 MBq). Blood
samples were collected at 1, 2, 5 min post-injection
and at 10, 20, 40 or 60 min post-injection when the
animals were sacrificed. Seven animals used for
metabolites analysis were also scanned for 60 min.
Plasma was isolated by centrifugation (3 min, 3000 × g
at 4 °C). Two hundred µL of CH3CN was added to 200
µL of serum for protein precipitation and after
centrifugation (3 min, 3000 × g at 4 °C), 100 µL of
supernatant was injected into the HPLC for
quantification
(HPLC
equipment:
Shimadzu
prominence with a UV detector and bespoke
Scintillation detector; column: ACE 3 C18 HL,
[Hichrom], 150 × 4.6 mm; porosity: 3 μm; solvent A:
0.1 M ammonium acetate; solvent B: CH3CN, isocratic
elution: 50:50 (A/B) in 15 min; flow rate: 1 mL/min;
room temperature; absorbance detection at λ = 254
nm). Animal brains were removed and then
homogenised by ultra-Turrax® in 2 mL of ice-cold
acetonitrile. After centrifugation (3 min, 9000 × g at 4
°C), the supernatant was separated from the pellet.
One hundred microliters of brain supernatant were

injected on the HPLC column (same conditions as
above). Control samples were spiked with 15 µL of
stable standard. The parent radiotracer eluted at 11
minutes.

AMPA lesion in Wistar rats
Three rats were anesthetized using isoflurane
(induction 4-5%, 2-2.5% thereafter in 70%/30%
NO2/O2 mixture) and stereotaxically injected with 7.5
nmol of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA, 7.5 mM in PBS buffer, Tocris
Bioscience, UK) through the use of a 2 µL
microsyringe (Hamilton Neuros syringe Model
7002KH point style 3) and micropump (injection rate:
0.5 µL/min, UltraMicroPump II and Micro4
Controller, WPI Inc., USA) in the right striatum
(Bregma +0.7 mm, from sagittal suture: 3 mm, depth
from brain surface: 5.5 mm). Animals were
maintained normothermic (body temperature: 37.0 ±
0.4 °C) during the surgery through the use of a
heating blanket (Homeothermic Blanket Control Unit,
Harvard Apparatus Limited®, Edenbridge, Kent,
UK). Twenty-four hours later, the rats were
anesthetized again as described above and scanned
with a 3T cryogen-free MRS 3000 scanner with a
quadrature, rat head coil (MR Solutions, Guildford,
UK) [34, 35] to assess oedema (i.e. lesion size and
location) immediately before the PET scan.
Parameters for the T2-weighted RARE sequence were:
repetition time = 4800 ms, base echo time = 17 ms,
effective echo time = 68 ms, number of echoes = 8,
bandwidth = 20 kHz, number of samples = 256,
number of views = 240, number of averages = 1 with
25 slices of 1.06 mm, giving a final voxel size of 0.136 ×
0.136 × 1.06 mm.

Animal PET and data acquisition
Sixty minutes PET scans were performed on 23
animals on a Siemens Inveon® PET/CT scanner
(Injected dose: 38±11MBq). Eight of them were used
for basal uptake. To assess the in vivo specificity of
18F-IAM6067, 2 of those eight rats were also used for
the pre-saturation protocol (BD1047) on a different
day. Nine rats were scanned for pre-saturation studies
with haloperidol (n = 3 scans) and/or BD1047 (n=4
scans) and/or SB206553 (n = 5 scans) on different
days. An additional three rats were scanned with
http://www.thno.org
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alone and 3 days later with 18F-IAM6067
after pre-treatment with the S2R antagonist CM398
[36]. These pre-saturation studies were conducted by
injecting 1mg/kg of haloperidol (D2/σ receptor
antagonist; Tocris Bioscience, UK; n = 3) [37, 38],
BD1047 (S1R antagonist; Tocris Bioscience, UK; n = 4)
[39], SB206553 (5-HT2B/5-HT2C receptor antagonist;
Tocris Bioscience, UK; n = 5) or CM398 (S2R
antagonist, kindly provided by Dr McCurdy; n = 3)
i.v. 20-30 min before scan start. Animals scanned on
multiple occasions (with/without blocking or
different blocking agent) were always scanned at least
24 h apart. Three additional rats received intra-striatal
AMPA and were scanned with 18F-IAM6067 24 h after
lesion. Each rat was anesthetized using isoflurane
(induction 4-5%, 2-2.5%) and catheterized in the tail
vein for blocking agent and 18F-IAM6067 injection.
Animal respiration and temperature were controlled
using a pressure-sensitive pad and rectal probe
(BioVet, m2m Imaging Corp., Cleveland, OH, USA)
and body temperature was maintained at 37 ± 0.7 °C
via the interface managed by the BioVet system.
PET-CT was performed as previously described [40].
Briefly, a CT scan was performed prior to the PET
acquisition for attenuation correction. The list mode
emission data were histogrammed into 3D sinograms
of 35 dynamic frames, normalized, corrected for
dead-time, attenuation, scatter and radioactive decay,
and reconstructed using OSEM3D (16 subsets and 4
iterations) into images of dimensions 128 × 128 × 159
voxels of volume 0.776 × 0.776 × 0.796 mm3.

PET image analysis
PET-CT images were co-registered with the rat
MRI template and its associated intracranial mask as
published by Schwarz et al. [41] and generously
provided by GSK. To co-register the MRI template
and PET-CT images, individual brain masks were
delineated on each CT image and co-registered with
the MRI brain mask using rigid registration with
mutual
information.
Image
analysis
and
quantification was performed using the BrainVisa/
Anatomist software (http://www.brainvisa.info)
using the geometric transfer matrix (GTM) and
ROIopt methods for partial volume correction both
described and used previously [42-46]. Modified
larger ROIs were drawn on the MRI anatomical
template [41] for 18F-IAM6067 quantification. PET
data were expressed as SUV.

Parkinson’s disease mouse model
C57Bl6 mice were bred in the animal facility of
the European Institute for Molecular Imaging
(University of Muenster). Animal experiments were
performed in accordance with the German laws for
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animal protection and were approved by the local
bureau for animal care (LANUV, Landesamt für
Natur, Umwelt und Verbraucherschutz NordrheinWestfalen). For stereotactic injections, mice (n = 6)
were anaesthetised (ketamine/xylazine i.p.) and
placed into a stereotactic frame. A small skin incision
followed by craniotomy was performed. The needle
was placed in position (coordinates: AP: +0.5 mm;
ML: -2.0 mm; DV: -3.0 mm) and after 1 min, 2 µL of 5
mg/mL 6-hydroxydopamine (6-OHDA) in 0.9% NaCl
and 0.02% ascorbic acid were injected into the left
striatum using a 5 µL Hamilton 7005KH syringe. The
syringe was kept in place for 5 min in order to allow
the solution to diffuse into the surrounding tissue and
was then retracted slowly.

Human tissue
Post-mortem brain tissues of 23 cases (8 men and
15 women) were obtained from the Manchester Brain
Bank through appropriate consenting procedures for
collection and use of the human brain tissues.
Pathological diagnoses were made by an experienced
neuropathologist (DM) as previously described [47,
48] and were in accordance with recent National
Institute on Ageing - Alzheimer's Association
guidelines for the neuropathological assessment of
AD [49]. By such classification, only cases with Braak
stages 5 and 6 were classed as definite AD. Cases with
Braak Stages >2 & ≤4 were not diagnosed as definite
AD, but these could be considered as cases of possible
(incipient) AD, thereby representing cases with early
changes of AD. Amyloid plaque load per se was not
employed for classification of AD, although it is
acknowledged that neuritic plaque scores do form the
basis of CERAD classification. Clearly, in terms of
amyloid plaques alone, there was overlap in amyloid
load between cases at Braak stage >2 & ≤4 and those at
Braak stages 5 and 6. Subjects were therefore split in
three groups based on their Braak stages [33]: controls
(Braak ≤2, 8 subjects), subclinical AD (Braak >2 & ≤4, 8
subjects) and AD (Braak >4, 7 subjects). Details of each
case are described in Table 1. Hence, brains in the first
group were considered as a (normal) control group
(Braak ≤2). These were obtained from aged patients
with no history of neurological disease and no
pathological evidence of AD or other degenerative
brain disease. The second group (Braak >2 & ≤4)
consisted of patients with mild to moderate AD-type
pathology, whilst the last group (Braak >4) all showed
abundant plaques and tangles throughout all cortical
regions and met pathological criteria for established
AD [49, 50]. The average post-mortem delay was also
similar for all groups (mean ± SD [min.-max.]: 34.9 ±
11.3 [12-46]; 35.8 ± 9.9 [25-48] and 41.5 ± 14.2 [24-64]
hours for controls, subclinical AD and AD groups,
http://www.thno.org
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respectively). Subsequently to the autoradiography
experiments, measurements from frontal cortex of
case #3 were not included as the sections had been
damaged during the experiments (Table 1).

Immunohistochemistry
Two weeks after 6-OHDA lesion, animals were
sacrificed by cervical dislocation and brains were
removed and frozen in -40°C isopentane.
Cryosections of 20 µm thickness were cut every
500µm, resulting in 16 levels per brain. In order to
assess the effect of the 6-OHDA on the striatal
dopaminergic neurons of the C57Bl6 mice,
immunohistochemistry for tyrosine-hydroxylase was
performed using the following protocol: brains were
post-fixed with 4% PFA in PBS for 15 min at 4 °C, then
washed with PBS (3 × 5min). For antigen retrieval,
sections were boiled for 25 min in citrate buffer (pH
6), left in the buffer to cool down for 20 min, and
washed with PBS (3 × 5 min). Blocking was performed
with Peroxidase-blocking solution (S2023, Dako,
Hamburg, Germany) for 10 min followed by a PBS
washing step (3 × 5 min). After incubation with
primary antibody (chicken anti-tyrosine-hydroxylase,
Abcam ab76442, 1:800, Abcam, Cambridge, UK) over
night at 4 °C in antibody diluent (S3022, Dako),
sections were washed (PBS, 3 × 5 min), incubated with
biotinylated secondary antibody (DSB-XTM Biotin
Goat Anti-Chicken IgG 1:800, Life Technologies,
Carlsbad, CA, USA) in antibody diluent for 60min,
washed (PBS, 3 × 5 min) and incubated with HRP
Streptavidin conjugate (1:600 in PBS, P0397, Dako) for
45min. After washing (PBS, 3x5min), sections were
placed in 2% 3,3'-Diaminobenzidine (DAB), 0.0012%
H2O2 until reaching a good staining intensity. Sections
were dehydrated in 70 %, 80 %, 96% ethanol, 100%
isopropanol and xylene (each twice) and mounted in
Entellan (Merck Millipore, Burlington, MA, USA).
Images were collected on a Nikon ECLIPSE Ni-E
upright microscope using a 10×/0.30 or 20×/0.50
UPlanFLN objectives operated by the NIS Elements
AR software (Nikon Instruments Inc., Tokio, Japan).
Immunohistochemistry was also carried out in
rats that received intrastriatal AMPA to visualise
NeuN (neuronal marker). Animals were culled by
isoflurane overdose confirmed by cervical dislocation.
The brains were collected, snap frozen using
isopentane on dry ice and stored at -80 °C. Coronal
brain sections (20 µm thick) were taken using a
cryostat (Leica CM3050s, Leica Biosystems Nussloch
GmbH, Germany) and stored at -80 °C. Sections were
allowed to defrost and dry at room temperature for
20min and then fixed with 4% paraformaldehyde for
10 min before being washed (6 × 5 min) in phosphate
buffered saline (PBS) and incubated for 30 min in 2%
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normal donkey serum and 0.1% Triton X-100 in PBS to
permeabilise and block non-specific binding. Primary
antibody incubation was carried out overnight at 4 °C
with rabbit anti-NeuN (Abcam, ab177487, 1:500).
Following incubation in primary antibody, PBS
washes were repeated (3 × 10min) and incubation
with the secondary antibody (Alexa Fluor 594nm
Donkey anti-rabbit IgG 1:500) was carried out. Images
of the lesioned striatum were collected on an
Olympus BX51 upright microscope using a 10×/0.30
UPlanFLN objectives and captured using a Retiga
6000 Color and R6 camera through QCapture Pro 7
and Ocular Software (QImaging Inc.). Specific band
pass filter sets were used to prevent bleed through
from one channel to the next. NeuN staining was
quantified using ImageJ (1.52n) [51-53] using 5
snapshots for the caudate putamen, 3 snapshots for
the globus pallidus and 2 snapshots for the substantia
nigra for each side of the brain (ipsi- and
contralateral). Both the total number of neurons
averaged over the snapshots and the percentage of
stained areas were measured.

Autoradiography
18F-IAM6067

autoradiography was performed
using 20µm fresh frozen brain sections from 6 naïve
and 3 AMPA-injected Wistar rats, 6 C57Bl6 mice and
also from the 23 human cases. Sections of frontal
(Brodmann areas 8/9) and temporal cortex
(Brodmann areas 21/22) were cut from frozen human
tissue blocks. Human and rodents sections were
mounted on to glass slides (SuperFrost Plus Gold and
SuperFrost Plus slides, Thermo Fisher Scientific Inc.,
MA, USA for human and animal tissues,
respectively). For all steps described below, Tris
buffer (Trizma pre-set crystals (Sigma, UK), 50 mM,
with 120 mM NaCl, with pH adjusted to 7.4 at 4 °C or
room temperature) was used. Slides were allowed to
defrost then pre-incubated in Tris Buffer at 4 °C for
5min. Slides were then incubated with 18F-IAM6067 (2
nM) in Tris Buffer at room temperature for 60 min to
determine total binding. Adjacent sections were
incubated with the same solution containing an excess
of unlabelled IAM6067 (2 µM) to assess non-specific
binding. Next the slides were washed 2 × 2 min in Tris
buffer at 4 °C, followed by a quick rinsing in distilled
water at 4 °C. Slides were then dried promptly before
exposition on Phosphor-Imager plates overnight.
Autoradiographs were analysed using AIDA software
(Raytest GmbH, Germany). Regions of interest (ROI)
were manually drawn (amygdala, striatum, cingulate
cortex, sensorimotor cortex (SS), hippocampus,
hypothalamus, pons, thalamus medio-dorsal (MD),
region containing the ventral tegmental area and the
substantia nigra (VTA/SN) and the cerebellum for the
http://www.thno.org
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naive rat tissue; the ipsi- and contralateral striatum
(the ipsilateral striatum includes the lesioned part of
both the caudate-putamen and globus pallidus pooled
together notably because accurate anatomical
delineation of both brain regions on the
autoradiography was difficult) and cortex for the
AMPA-injected rats; the ipsi- and contralateral parts
of the cingulate cortex, striatum, CM thalamus and
VTA/SN for the mouse tissue; the grey and white
matter for the human tissue). Specific binding (total
binding minus non-specific binding) in each ROI is
expressed as intensity of the photostimulated
luminescence (PSL) per pixel.

Statistical analysis
All data are expressed as mean ± standard
deviation (SD). Statistical significance was accepted at
P<0.05 level. Statistical tests were performed using
GraphPad Prism 8.4 for Windows (GraphPad
Software, CA, USA, www.graphpad.com) and P
values adjusted for multiple comparisons are reported
for Sidak’s post-hoc tests.

PET data
For uptake of 18F-IAM6067 without and with
blocking compounds, values were analysed using 2
way ANOVA (ROI as repeated factor and treatment;
i.e. baseline vs blocking), the scans with haloperidol,
BD1047 or SB206553 pre-treatment were compared to
baseline scans. As the experiments with CM398 were
performed later, scans without and with
pre-treatment with CM398 were performed in the

same animals and therefore were analysed using 2
way ANOVA with repeated measures for ROI and
treatment. ANOVA were followed by a Sidak’s
post-hoc test. For comparisons between baseline vs
haloperidol, BD1047 and SB206553 pre-treatments
and baseline vs CM398, and between ROIs,
considering the large number of comparisons, the
more conservative option of one family for all
comparisons was applied for the Sidak’s post-hoc test.
For the AMPA experiment, comparison of
18F-IAM6067 uptakes by PET in ipsi- vs contralateral
vs lesion in the caudate-putamen and globus pallidus
(as delineated on the T2 MRI) ROIs and comparisons
all ROIs of control (no lesion) vs AMPA-injected
animals were performed using a 2 way ANOVA
followed by a Sidak’s post-hoc test.

Autoradiography data
Specific binding in the ipsi- and contralateral
striatum in the rat AMPA model was analysed with a
paired t-test.
Specific binding between the ipsi- and
contralateral parts of each region in the PD mouse
model 18F-IAM6067 autoradiography was analysed
using a 2 way ANOVA (both ROI and side, ipsi- vs
contralateral, as repeated factors). The 2 way ANOVA
only returned an effect of ROI (p=0.003) but no
significant differences between ipsi- and contralateral
side or interaction (p=0.84 and p=065 respectively),
therefore a Sidak’s post-hoc test comparing ROIs only
was performed.

Table 1. Clinical summary of autopsy cases used for the 18F-IAM6067 autoradiography experiments
Case no.
1
2
3*
4
5
6
7
8

Gender
M
M
F
F
F
F
F
F

Age of death (years)
54
95
72
81
82
89
87
92

PM delay (hours)
37
12
41
41
46
41.5
24
37

Principal pathological diagnosis
Normal brain
Age changes only
Age changes only
Age changes only
Age changes only
Age changes only
Age changes only
Age changes only

Age of disease onset (years)
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A

Braak stage
≤2
≤2
≤2
≤2
≤2
≤2
≤2
≤2

9
10
11
12
13
14
15
16

M
F
M
F
M
M
F
F

82
93
89
92
91
86
97
84

40
41
48
25
33
26
25
48

Moderate AD
Mild AD
Mild AD
Severe CAA
Moderate AD
AD
AD
AD

75
N/A
N/A
84
84
N/A
N/A
78

>2 & ≤4
>2 & ≤4
>2 & ≤4
>2 & ≤4
>2 & ≤4
>2 & ≤4
>2 & ≤4
>2 & ≤4

17
18
19
20
21
22
24

M
M
F
F
F
F
F

62
73
85
91
82
71
81

50
36
24
45
46
64
25.5

AD
AD
AD
AD
AD
AD
AD

56
60
N/A
N/A
68
64
74

>4
>4
>4
>4
>4
>4
>4

PM: post-mortem delay; CAA: cerebral amyloid angiopathy; AD: Alzheimer’s disease; N/A: not available/applicable. * Measurements from frontal cortex of case #3 were not
included as the sections had been damaged during the experiments.
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Specific binding for human autoradiography
across the three groups in both frontal and temporal
cortex and for grey and white matter was analysed by
mixed-model fitting (brain structures as repeated
factor). As this analysis only returned an effect for the
brain structures factor and not for the Braak stage, a
Sidak’s post-hoc test comparing brain regions only
was performed.

Immunohistochemistry data
For NeuN staining analysis and 18F-IAM6067
autoradiography in the AMPA model, percentage
stained area, cell counts and 18F-IAM6067 were
analysed using paired t-tests (ipsi- vs contralateral) for
the caudate-putamen, globus pallidus and substantia
nigra.

Results
Radiosynthesis
On average, about 2.96 GBq (range 0.53-11.3
GBq) of 18F-IAM6067 (>98.5% radiochemically pure)
were routinely obtained within 65 min of
radiosynthesis (including high-performance liquid
chromatography
(HPLC)
purification
and
formulation), with molar activities ranging from 55 to
345 GBq/µmol.

Metabolites analysis
Metabolites analysis revealed 3 fractions of the
radiotracer with retention times at 1.4 and 1.8 min for
metabolites and between 10.9 and 11.1 min for the
parent fraction (in the plasma and the brain,
respectively) (Table 2). Moreover, radiolabelled
metabolites analysis showed rapid metabolism of
18F-IAM6067 (only 10.1 ± 8.6% of intact tracer in
plasma at 10 min post-injection) (Table 2). On
contrary, more than 91% of the intact 18F-IAM6067
was found in the brain at 10, 20 and 60 min
post-injection. Metabolites represented only a minor
fraction of radioactivity found in the brain
(undetectable at 1, 2 and 5 min post-injection and less
than 10% at 10, 20 and 60 min post-injection) (Table 2).
The retention times of these 2 metabolites (1.4 and
1.8min, Table 2) suggest that they were more

hydrophilic than the parent compound.

Tracer brain uptake and distribution
The average brain uptake of the radiotracer
between 20 and 60 min post-injection in several brain
regions is shown in Figures 2 & 3. Pharmacokinetic
time-activity curves at baseline and after presaturation with BD1047 in the rat thalamus mediodorsal and amygdala highlighted the specificity of
18F-IAM6067 bindings for the S1R (i.e. full blocking by
BD1047, Figure 3A, C & E). 18F-IAM6067 brain uptake
was rapid and attained a maximum level (3.3 and 5.5
SUV in amygdala and thalamus medio-dorsal
respectively) at 2.25 min post-injection and then
progressively and slowly washed out up to 60min. At
baseline, the lowest average uptake of 18F-IAM6067
was detected in the caudate/putamen (2.3 ± 0.1 SUV),
in the cingulate cortex (2.3 ± 0.2 SUV) and the
temporal cortex (2.5 ± 0.2 SUV) (Figure 2A). The
highest uptakes were found in the substantia nigra (3.8
± 0.7), thalamus medio-dorsal (3.9 ± 0.4 SUV),
mesencephalic region (4.7 ± 0.3 SUV) and pons-raphe
(6.4 ± 0.8 SUV) (Figure 2A). Comparisons of
18F-IAM6067 uptake between all ROIs are shown
Figure 2B. Those results were confirmed by
18F-IAM6067 autoradiography in rat brain regions
which showed similar anatomical distribution of
18F-IAM6067 binding as the PET imaging (Figure 4).
The highest specific binding was observed in the pons
(7.24 ± 0.89 PSL/pixel) and the hypothalamus (6.79 ±
0.95 PSL/pixel) and the lowest specific binding in the
striatum (4.56 ± 0.42 PSL/pixel) and the cingulate
(4.96 ± 0.26 PSL/pixel) and somatosensory cortices
(4.49 ± 0.51 PSL/pixel) (Figure 4).
Pre-saturation
with
SB206553
(5HT2B/C
antagonist, blue bars, Figure 3C & E) or CM398 (S2R,
Figure 3B, D & E) did not reveal any significant
difference with baseline uptake. Pre-saturation
studies with haloperidol (D2/σ receptor antagonist;
orange bars) or BD1047 (S1R antagonist; red bars)
showed a significant decrease (between 79-90%) of
18F-IAM6067 uptake in all areas of the brain (Figure
3B, C & E) which abolished all differences between
ROIs.

Plasma

Metabolites

Rt

M1
M2
Parent
M1
M2
Parent

1.4
1.8
11.1
1.4
1.8
10.9

Time (min)
1
ND
ND
ND
8.9±8.1
7.0±0.0
88.8±12.1

2
ND
ND
ND
41.5±4.4
0.0
58.3±4.1

5
ND
ND
ND
77.6±11.6
0.0
22.4±11.6

10
5.6±2.7
3.9±2.0
91.3±3.7
84.4±17.3
24.4±5.8
10.1±8.6

20
3.8±1.9
2.6±0.8
94.1±2.8
87.3±19.1
24.1±20.0
9.8±4.2

60
8.0±6.2
1.5±0.7
91.3±6.0
99.7±0.8
2.1±0.0
0.0

Percentage of
18F-IAM6067
and metabolites

Brain

Table 2. Percentage of 18F-IAM6067 (parent fraction and metabolites) in rat brain and plasma at 1, 2, 5, 10, 20 and 60 min post-injection.
Rt indicates the retention time of each fraction of the radiotracer. Data expressed as mean ± SD

M1: metabolite 1; M2: metabolite 2; ND: not determined. Rt = retention time (min).
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Figure 2. (A) Average uptake (from sum-image 20-60min post-injection) of 18F-IAM6067 in different brain regions in rats (n=8, data are expressed as SUV mean ± SD). (B) Heat
map of the adjusted P values (Sidak’s post-hoc test) showing all the comparisons between the various brain regions for 18F-IAM6067 uptake. Non-significant differences are shown
in blue. (C) PET sum-image (20-60min) co-registered with CT showing 18F-IAM6067 uptake with hippocampus, thalamus medio-dorsal, frontoparietal somatosensory cortex and
amygdala highlighted by dotted lines.
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Figure 3. Pharmacokinetic time-activity curves in rat thalamus medio-dorsal and amygdala showing 18F-IAM6067 uptake at baseline (n=8) and after pre-saturation with S1R
antagonist BD1047 (n=4) (A) or at baseline (n=3) and after pre-saturation with S2R antagonist CM398 (n=5) (B). (C) Comparison of average uptake (from sum-image 20-60min
post-injection) of 18F-IAM6067 between baseline (no pre-treatment, n=8, green bars) and SB206553 (n=5, blue bars), haloperidol (n=3, orange bars) or BD1047 (n=4, red bars)
pre-saturations and (D) between baseline and CM398 pre-treatment (n=3) in different brain regions (Data are expressed SUV mean ± SD). (E) Co-registered PET-CT images
showing 18F-IAM6067 uptake at baseline and with pre-saturation with haloperidol, SB206553, BD1047 or CM398 (sum-image 20-60min after injection of the radiotracer); outline
of the frontoparietal somatosensory cortex (dark red), hippocampus (yellow), thalamus medio-dorsal (purple) and amygdala (orange) regions of interest are shown.
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Figure 4. (A) quantification of 18F-IAM6067 specific binding as measured in rats by in vitro autoradiography in various brain regions. Data expressed as mean ± SD (n=6) of
photostimulated luminescence (PSL) unit per pixel. VTA/SN: ventral tegmental area/substantia nigra. (B) Representative autoradiograms showing total and non-specific binding in
different rat brain regions.

Excitotoxic lesion model in rats
AMPA injection in the striatum resulted in a
significant neuronal loss 24h post-injection
characterised by oedema visible on the T2 MRI
(Figure 5A) and as quantified by NeuN staining
(Figure 6). 18F-IAM6067 PET imaging revealed only a
non-significant trend to decrease in 18F-IAM6067
uptake in the caudate-putamen (-16 ± 11%, Figure 5B)
despite a significant loss of neurons (-81 ± 3% in %
stained area and -71 ± 3% in cell number, Figure 6A),
18F-IAM6067
uptake was however significantly
reduced in the globus pallidus (-69 ± 5%, Figure 5B)
matching the significant loss of neurons detected by
NeuN immunohistochemistry in this ROI (-71 ± 8% in
% stained area and -56 ± 17% in cell number, Figure
6B). Comparing all the ROIs in control animals (no
lesion) with AMPA-lesioned rats revealed a
significant increase in 18F-IAM6067 uptake in both
ipsi- and contralateral Substantia nigra and pons-raphe
(Supplementary Figure 1A and B) although no
changes in NeuN immunostaining could be detected
in those brain regions (Supplementary Figure 1C);
18F-IAM6067 uptake was not affected in any other
brain areas (Supplementary Figure 1A and B).
The post-mortem autoradiographic analysis of
the 18F-IAM6067 binding in the ipsi- vs contralateral
striatum (caudate-putamen + globus pallidus) of the
same animals revealed a significant decrease (-38 ±
8%, Figure 5C & D).

6-OHDA Parkinson’s disease model in mice
In the PD mouse model, the 2 way ANOVA
returned an effect of ROI (p=0.003) only. No
differences between ipsilateral and contralateral sides
or interaction ROI × side were identified (p=0.84 and

p=0.65 respectively) (ipsi- vs contralateral; cingulate
cortex: 4.21 ± 0.87 vs 4.29 ± 0.84 PSL/pixel, striatum:
3.39 ± 0.49 vs 3.30 ± 0.55 PSL/pixel, thalamus
medio-dorsal: 3.25 ± 0.64 vs 3.22 ± 0.65 PSL/pixel and
ventral tegmental area/substantia nigra: 3.82 ± 1.25 vs
3.92 ± 1.08 PSL/pixel) despite evidence of a clear
lesion of the dopaminergic neurons as detected by
tyrosine hydroxylase immunohistochemistry (Figure
7).

Autoradiographic study of brains from
Alzheimer’s disease patients
The specific binding of 18F-IAM6067 was also
investigated by autoradiography in the grey matter of
controls (Braak stage ≤2), subclinical AD (Braak stage
>2 & ≤4) and AD (Braak stage >4) subjects in the
frontal and in the temporal cortex. Only a significant
difference between grey and white matter could be
detected, white matter being significantly lower than
grey matter (Figure 8). No differences between Braak
stage or interaction brain structures × Braak stage
were detected (p=0.095 and p=0.91, respectively) (2.37
± 1.09 vs 3.11 ± 0.84 vs 3.27 ± 0.90 PSL/pixel, for
controls, subclinical AD and AD groups, respectively,
in the frontal grey matter and 2.56 ± 1.24 vs 2.98 ± 1.15
vs 2.91 ± 1.20 PSL/pixel, for controls, subclinical AD
and AD groups, respectively, in the temporal grey
matter) (Figure 8).

Discussion
Brain uptake, distribution and selectivity of
18F-IAM6067
Here we investigated the S1R PET tracer
and demonstrated that brain distribution
was in good agreement with the known distribution
18F-IAM6067
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of S1R in the rat brain [54-56]. Despite rapid
metabolism in plasma, 18F-IAM6067 brain uptake was
fast and allowed for accurate and specific
quantification of S1R by PET imaging. Using two
different animal models of neurodegeneration and
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human brain samples, our results suggest that the
expression levels of S1R might not be directly related
to neuronal loss and might be subject to more
complex regulation.

Figure 5. (A) representative 18F-IAM6067 PET-MR fused image and T2-MR image (insert, with the lesion in the globus pallidus as delineated on the T2 image in pink) 24h after
intra-striatal injection of AMPA (7.5 nmol). (B) Quantification of the 18F-IAM6067 uptake in the ipsilateral (healthy), contralateral and lesioned Caudate-Putamen and Globus
pallidus. (C) Representative autoradiograms of the same rat brain than in (A) showing the total and non-specific binding of 18F-IAM6067. The location of the lesion (minus piece
of missing tissue indicated by the dashed pattern) is delineated by red dotted line and arrows while the contralateral side is delineated by green dotted line and arrows. (D)
Quantification of the specific binding as quantified by autoradiography in the cortex and contralateral and ipsilateral caudate-putamen+globus pallidus. Data are expressed as mean
± SD (n=3). PET data were analysed with a 2 way ANOVA (brain structures & side, ipsi- vs contralateral) followed by a Sidak’s post-hoc test. Contra- and ipsilateral sides for the
autoradiography were compared with a paired t-test. * And *** indicates p<0.05 and p<0.001 respectively.
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Figure 6. Quantification of the neuronal density (as percentage of stained area and cells/mm²) (left panel) and representative images of the NeuN immunostaining in the ipsi- and
contralateral side of the caudate-putamen (A) and globus pallidus (B) 24h after intrastriatal AMPA injection in rats. Data are shown as mean ± SD. Data were analysed using paired
t-tests. * And ** indicate p<0.05 and p<0.01 respectively.
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Figure 7. (A) Quantification by autoradiography of the 18F-IAM6067 specific binding in various contralateral and ipsilateral brain regions of the 6-OHDA Parkinson’s disease
mouse model. Data are expressed as mean ± SD (n=7). (B) Representative autoradiograms of a mouse brain showing the total and non-specific binding of 18F-IAM6067. (C)
Representative immunohistological staining against tyrosine hydroxylase (Tyr-OH IHC) showing the significant loss of dopaminergic neurons in the ipsilateral striatum. The
location of the lesion is delineated by red dotted line and arrows while the contralateral side is delineated by green dotted line and arrows on both the autoradiograms and
immunostaining. NS: non-specific; CG: cingulate cortex; MD: medio-dorsal; VTA/SN: ventral tegmental area/substantia nigra. Data were analysed using a 2 way ANOVA (brain
structures & side, ipsi- vs contralateral), there was no significant differences between ipsi- and contralateral side and no significant interaction between ROI and side.

Figure 8. Quantification by autoradiography of the 18F-IAM6067 specific binding in the grey (top panel) and white matter (bottom panel) of control subjects (Braak ≤2, n=7-8),
subclinical AD (Braak >2 & ≤4, n=8) and AD patients (Braak >4, n=7) in frontal cortex (left panel) and in temporal cortex (right panel). Data are expressed as mean ± SD. Data
were analysed by mixed-model fitting (brain structures as repeated factor). As this analysis only returned an effect for the brain structures factor (p<0.001) and not for the Braak
stage (p=0.095) or interaction brain structure × Braak stage (p=0.91), a Sidak’s post-hoc test comparing brain regions only was performed, for both brain structure and all Braak
stage, specific binding in white matter was significantly lower than in grey matter.
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The S1R-system regulates most of the major
neurotransmission systems such as cholinergic,
noradrenergic and dopaminergic systems [10] in the
CNS and as such S1R has emerged as a potential
biomarker of neuronal function. For example, Mishina
et al. have reported a decrease in S1R density in PD
patients [17] in the anterior putamen and reduction in
cortical and cerebellar S1R density in brains of AD
patients [18] and others have reported decreases in
S1R density in post-mortem tissue of AD patients [19,
20]. Therefore, the evaluation of suitable (i.e. high
selectivity notably vs S2R and other targets) S1R
radiotracers is still required to investigate S1R density
non-invasively in vivo, notably because many S1R
tracers developed in the past displayed low affinity
for S1R, unfavourable brain penetration [57] and/or
insufficient σ1/σ2 selectivity. 18F-FTC-146 [26] and
18F-fluspidine [27] are however the two noteworthy
exceptions of previously reported 18F-labelled S1R
tracers with high S1R affinity and σ1/σ2 selectivity.
18F-FTC-146 has been used in a preclinical model [58]
and in a clinical case of peripheral injury [59] although
it was also found to have slow brain pharmacokinetic
for its use in human [30, 31]. Conversely, (S)-18Ffluspidine seems to have suitable pharmacokinetics
and metabolism in human [60, 61] and is now being
used in clinical studies [62, 63]. 18F-IAM6067 had
already been shown to have sufficient selectivity
against S2R (Ki σ2/σ1 = 187) and other targets (see
supplementary data in [29] in which 18F-IAM6067 is
compound #30 page S3). We present here the
evaluation of 18F-IAM6067 as a S1R specific PET tracer
and confirmed its σ1/σ2 suitable selectivity in vivo
(Figure 3D). Metabolite analysis revealed a rapid
metabolism of the parent fraction of 18F-IAM6067 in
rat plasma (approximatively 10% at 10 and 20 min,
and not detectable at 60 min post-injection) (Table 2).
Conversely, in brain most of the radioactivity detected
was due to the parent compound (≥91% of the intact
tracer at 10, 20 and 60 min post-injection) and only a
small amount of metabolites detected in plasma could
be detected in brain. While we cannot totally exclude
that the metabolites were able to cross the blood-brain
barrier (BBB), the small amount detected (8.0 ± 6.2% of
the total activity 60 min post-injection) as well as the
low HPLC retention time (1.4 and 1.8min), suggesting
a high hydrophilicity, support the hypothesis that the
metabolites detected in brain are from blood left in the
samples rather than from crossing the blood brain
barrier. This would therefore support the notion that
the 18F-IAM6067 brain signal detected in our
experiments was most likely caused by intact
radiotracer in the brain. Pre-saturation studies with
haloperidol (non-selective Dopamine D2/σ1 receptors
antagonist) or BD1047 (S1R specific antagonist)
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resulted in 79-90% blocking of 18F-IAM6067 uptake
(see Figure 3A, C & E) and abolished all ROI
differences, hence indicating presence of specific
binding in all brain areas. To further verify the
selectivity of 18F-IAM6067 vs S2R, we performed
repeated scans with and without pre-saturation with
the highly selective S2R ligand CM398 (Ki σ1/σ2 = 331)
[36]. Injection of cold CM398 did not result in a
significant reduction of 18F-IAM6067 uptake (Figure
3B, D & E). We also assessed specificity towards
5HT2B/C receptors as Moussa et al. [29] reported a Ki
ratio (5HT2B/S1R) of only 37, when compared with
the σ2/σ1 ratio of 187. Our pre-saturation experiment
using 5HT2B/C antagonist SB206553 showed no
significant difference in brain uptake in any of the
brain ROIs studied (Figure 3C & E), hence supporting
the selectivity of 18F-IAM6067 towards S1R vs 5HT2B/C
receptors. Overall, the results of the pre-saturation
studies and the presence of specific binding
throughout the brain are in agreement with the
previous reports [10, 28]. However, the presence of
specific binding in all ROIs prevents the use of any
brain region as a reference tissue for modelling
purpose. From an anatomical point of view, our
autoradiography study in rats was in good agreement
with our in vivo PET study. Overall, these results
validate the fact that 18F-IAM6067 is a suitable specific
and selective S1R radiotracer, although the slow
pharmacokinetic of 18F-IAM6067 in primate [28] may
limit its usefulness in clinical studies.

Evaluation of 18F-IAM6067 and S1R as
biomarker of neuronal loss
The second objective of this study was to assess
S1R as a biomarker of neuronal function in focal
neurodegenerative disease models. First, we used an
acute model of neurodegeneration induced by AMPA
excitotoxicity in the striatum. As previously reported
by us and others [64-66], intrastriatal injection of
AMPA induces robust neuronal death within 24h
followed by a neuroinflammatiory response. Here we
obtained a consistent 70-80% loss of neurons in the
striatum as demonstrated by NeuN immunostaining
(Figure 6), but despite this the decrease in
18F-IAM6067 uptake as quantified by PET was
inconsistent, with a significant decrease in the globus
pallidus (Figure 5B) but only a trend to a decrease in
the caudate-putamen; although the autoradiography
analysis revealed a more consistent -38% decrease in
specific binding in both the caudate-putamen and
globus pallidus. The inconsistency between PET
imaging, autoradiography and immunohistochemistry could be due to partial volume effect for the
PET imaging, the lesioned areas (caudate putamen
and globus pallidus) are amongst the ROIs with the
http://www.thno.org
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lowest level of S1R and are surrounded by other brain
region in which the 18F-IAM6067 uptake is higher,
consequently spill over in the lesion might explain the
lack of amplitude in the decrease of PET signal when
compared to autoradiography. The presence of focal
lesion is also a different paradigm than assessed by
Ishiwata et al. [67] and Ramakrishnan et al. [68] which
studied the effect of aging on S1R binding. Firstly,
these two reports investigated the overall effect of
aging on the brain levels of S1R rather than disease
associated neurodegeneration. Secondly, it is
noteworthy that these two publications report
contradictory results; Ishiwata et al. [67] reported a
significant increase (×4.57 fold) in Bmax accompanied
by a significant decrease in affinity (increased Kd,
×3.75 fold), resulting in an overall slight increase (×1.2
fold) in S1R binding potential (BPND) whereas
Ramakrishnan et al. [68] reported a significant
decrease (approximately 2 fold) in S1R BPND.
Furthermore, two different strain of rats were used in
these 2 studies: Fisher-344 [67] and Wistar Hannover
rats [68], so possible differences between strains
cannot be ruled out. Moreover, the results of Ishiwata
et al. [67] demonstrating a modulation of both Bmax
and Kd suggests a fine functional modulation of S1R
rather than only a direct relation with neuronal loss.
Interestingly, our observation of an increase in S1R in
the substantia nigra (Supplementary Figure 1A & B)
supports this theory of a fine modulation of S1R in
response to neuronal stress or loss. So far, the
meaning of such modulation of S1R in term of
neuronal functionality remains to be elucidated.
Second, we used 6-OHDA-lesioned mice, one of the
most accepted animal models for PD [69]. In this
model, we were not able to find any difference in
18F-IAM6067 specific binding between the ipsilateral
and contralateral hemispheres in the cingulate cortex,
striatum, thalamus medio-dorsal and VTA/SN,
despite clear loss of tyrosine hydroxylase positive
neurons in the striatum (Figure 7), showing that the
density or expression of S1R was not sensitive to the
loss of these neurons. This result is in contradiction
with the results by Mishina et al. [17] who investigated
S1R density in 6 PD patients vs 6 controls by
11C-SA4503 PET. They demonstrated a decrease in
S1R binding potential (BP) but only in the most
affected anterior putamen (as assessed by 11C-CFT for
dopamine transporter and 11C-raclopride for D2
receptor PET imaging) but interestingly did not detect
differences between controls and PD patients when
measuring 11C-SA4503 in the anterior putamen
bilaterally [17]. They suggested that this result
supported the use of S1R BP as marker of loss of
presynaptic dopaminergic neurons in PD [17]. One
must consider that the 6-OHDA model do not
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reproduce all the hallmarks of the human disease [70]
and that Mishina et al. performed an in vivo PET
imaging study whereas we used ex vivo
autoradiography in mice, so differences in techniques
and human vs animal model may have contributed to
the discrepancy between the two studies. Finally, the
studies cited above used 11C-SA4503 while we used
18F-IAM6067, and differences in binding sites between
these ligands cannot be ruled out to explain potential
differences between our results and those reported in
these studies.
In order to further investigate whether S1R
density is a reliable and sensitive biomarker of
neuronal loss/dysfunction, we also used post-mortem
brain sections from AD patients. Again, we showed
no difference in 18F-IAM6067 specific binding in the
frontal and temporal cortices between control
subjects, patients with mild to moderate AD-type
pathology and patients with established AD. Our data
are in disagreement with previous data from the
literature looking at AD patients. Indeed, the binding
potential of 11C-SA4503, used in a 90min PET study,
was significantly reduced in the frontal, temporal and
occipital cortex as well as in the cerebellum and the
thalamus in AD patients vs controls [18]. Furthermore,
Hedskog et al. [20] found a decrease of S1R expression
in post-mortem AD cortical tissue by Western blot
compared
to
controls.
Additionally,
an
autoradiography study revealed a decrease (26%) in
3H-DTG binding in the hippocampus of AD patients
vs controls [19]. Conversely, Hedskog et al. [20] also
showed that S1R was up-regulated in a mouse model
of AD [20] while σ2 receptor density was decreased in
a mouse model of AD in cortical regions and the
striatum of female, but not male, mice [71]. Again,
differences between animal models and human
disease could have contributed to the discrepancies
between studies. However, there is also a discrepancy
between our autoradiography study and the one by
Jansen et al. [19], but it must be noted that 3H-DTG has
a Ki vs non-selective S1R ligand haloperidol and
opioid receptor ligand pentazocine of only 5 and
42nM respectively [72] so is not as specific for S1R as
18F-IAM6067. This poor selectivity might have led to
the observation of decreases in binding sites
encompassing S1R as well as other binding sites such
as opioidergic receptors, which we have
demonstrated to be very sensitive to neuronal loss in
stroke [73, 74]. Finally, there are other points to take
into consideration when comparing our results with
those previously published. Firstly, our control group
pools together ‘true’ control cases (i.e. Braak 0) with
Braak stage ≤2, this may have biased the value in our
control group, although it is unlikely since these
patients had no history of neurological disease and no
http://www.thno.org
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pathological evidence of AD or other degenerative
brain disease. Moreover,
we know
from
neuropathological analysis that the brain of patients
in the moderate and severe AD had far more
degeneration and advanced neuropathology than
those in the control group [75]. Secondly, the number
of cases used in the study by Hedskog et al. [20] was
lower (3 and 3) than in our study where we used 23
cases split in 3 groups (n=7-8 per group), which
would seem more robust. Thirdly, the cases of our
study had a higher post-mortem delay (38.6 ± 12.9
hours for all patients) than those used by Hedskog et
al. [20] (between 10 and 30 hours) or Jansen et al. [19]
(14 ± 5 and 12 ± 6 hours for AD patients and controls,
respectively), and while these were the cases with the
shortest post-mortem delay we could access, this may
have influenced the quality of the tissue and the levels
of detectable S1R. Finally, age is the best known risk
factor for AD [76], so it is important to know how S1R
expression changes with age. Overall, it was shown
by PET imaging in rats that S1R could be either
slightly increased [67] or decreased [68] with age,
while in AD S1R has been shown to increase in animal
model [20] but conversely to decrease in human
studies [18-20]. Therefore, prediction of how S1R
density might evolve in neurodegenerative disease
such as AD, and the use of S1R as direct marker of
neuronal loss, might not be as straight forward as it
once seemed with age being a significant confounding
factor.
While we cannot totally rule out a potential lack
of sensitivity of 18F-IAM6067 in our experimental
settings, the absence of decreases in S1R binding in
the mouse PD model and AD brains, the increase in
the substantia nigra in the AMPA model in rats
(Supplementary Figure 1A & B), taken together with
previous reports [17, 18, 20, 67, 68] suggest that S1R
expression and/or binding characteristics are altered
differently in different population of neurons or
depending on the paradigms. In the absence of similar
studies in animal models of neurodegeneration and
human with tracers such as 18F-fluspidine and
considering that S1R is a chaperone protein and not a
neurotransmitter receptor, our results suggest that the
interpretation of changes in S1R PET tracer uptake
may be more difficult to interpret than initially
thought as these may not purely reflect a neuronal
loss or dysfunction but also more complex
compensatory mechanisms.

Conclusion
The present in vivo PET study in rats shows that
18F-IAM6067 is a suitable specific and selective S1R
radiotracer in rodent. Considering the relatively slow
pharmacokinetics in baboon shown by Moussa et al.
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[28], 18F-IAM6067 may not provide any advantage
over the currently used (S)-18F-fluspidine for imaging
S1R in human [62, 63]. Our data in the rat AMPA,
mouse PD models and in human brain tissue did not
allow us to conclude positively on the potential use of
S1R as biomarker for neuronal (dys)function in
neurodegenerative conditions such as AD or PD.
Reports about changes in S1R density with age and
disease are conflicting so far, and with the emergence
of S1R as a potential therapeutic target in
neurodegenerative diseases and in tumours, further
elucidation of the expression, function, density and
role of S1R is of highest interest. Overall the
previously published data and the present study
warrant further investigations on the S1R-system in
health and disease.
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